BioVie (BIVI) 10-K 24 Sep 14 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Jun. 30, 2014	Sep. 23, 2014	Dec. 31, 2013
Document And Entity Information	'	'	'
Entity Registrant Name	'NANOANTIBIOTICS, INC.	'	'
Entity Central Index Key	'0001580149	'	'
Document Type	'10-K	'	'
Document Period End Date	30-Jun-14	'	'
Amendment Flag	'false	'	'
Current Fiscal Year End Date	'--06-30	'	'
Is Entity a Well-known Seasoned Issuer?	'No	'	'
Is Entity a Voluntary Filer?	'No	'	'
Is Entity's Reporting Status Current?	'Yes	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Public Float	'	'	$8,706,000
Entity Common Stock, Shares Outstanding	87,210,000	87,210,000	'
Document Fiscal Period Focus	'FY	'	'
Document Fiscal Year Focus	'2014	'	'

Balance_Sheets

Balance Sheets (USD $)	Jun. 30, 2014	Jun. 30, 2013
CURRENT ASSETS:	'	'
Cash	$332,864	$505,696
Total Current Assets	332,864	505,696
TOTAL ASSETS	332,864	505,696
CURRENT LIABILITIES:	'	'
Accounts Payable	'	15,000
Accrued Payroll	161,475	'
Total Current Liabilities	161,475	15,000
STOCKHOLDERS' EQUITY	'	'
Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding	'	'
Common stock, $0.0001 par value; 300,000,000 shares authorized; 87,210,000 and 87,060,000 shares issued and outstanding, respectively	8,721	8,706
Capital in excess of par value	514,485	499,500
Prepaid services paid for with common stock	-12,411	'
Accumulated deficit	-339,406	-17,510
Total Stockholders' Equity	171,389	490,696
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$332,864	$505,696

Balance_Sheets_Parenthetical

Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Statement of Financial Position [Abstract]	'	'
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	300,000,000	300,000,000
Common Stock Shares Issued	87,210,000	87,060,000
Common stock, shares outstanding	87,210,000	87,060,000

Statements_of_Operations

Statements of Operations (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
REVENUE:	'	'
Sales	'	'
COST OF GOODS SOLD	'	'
GROSS MARGIN	'	'
OPERATING EXPENSES	'	'
Research and development expenses	49,419	'
Payroll expenses	161,475	'
Professional fees	85,602	'
Selling, general and administrative expenses	25,889	17,515
TOTAL OPERATING EXPENSES	322,385	17,515
LOSS FROM OPERATIONS	-322,385	-17,515
OTHER EXPENSE (INCOME)	'	'
Interest Expense	'	'
Interest income	-489	-5
TOTAL OTHER EXPENSE (INCOME)	-489	-5
NET LOSS	($321,896)	($17,510)
NET LOSS PER COMMON SHARE, BASIC AND DILUTED	$0	$0
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING, BASIC AND DILUTED	87,083,596	41,226,379

Statement_of_Shareholders_Equi

Statement of Shareholders Equity (USD $)	Common Stock	Capital in excess of par value	Prepaid Services Paid with Common Sock	Accumulated Deficit	Total
Beginning Balance at Apr. 09, 2013	'	'	'	'	'
Beginning Balance (in shares) at Apr. 09, 2013	'	'	'	'	'
Issuance of Founder shares ($0.0001 per share)	8,206	'	'	'	8,206
Issuance of Founder shares (in shares)	82,060,000	'	'	'	'
Issuance of common stock for cash ($0.10)	500	499,500	'	'	500,000
Issuance of common stock for cash (in shares)	5,000,000	'	'	'	'
Net Loss	'	'	'	-17,510	-17,510
Ending Balance at Jun. 30, 2013	8,706	499,500	'	-17,510	490,696
Ending Balance (in shares) at Jun. 30, 2013	87,060,000	'	'	'	'
Issuance of common stock for services, $0.10	15	14,985	-12,411	'	2,589
Issuance of common stock for services, (in shares)	150,000	'	'	'	'
Net Loss	'	'	'	-321,896	-321,896
Ending Balance at Jun. 30, 2014	$8,721	$514,485	($12,411)	($339,406)	$171,389
Ending Balance (in shares) at Jun. 30, 2014	87,210,000	'	'	'	'

Statement_of_Shareholders_Equi1

Statement of Shareholders Equity (Parenthetical) (USD $)	Jun. 30, 2014
Shares Issued, Price Per Share	$0.10
Founder [Member]	'
Shares Issued, Price Per Share	$0.00

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'
Net loss	($321,896)	($17,510)
Amortization of prepaid common stock for services	2,589	'
Adjustments to reconcile net loss to net cash to cash used by operating activities:	'	'
Accounts Payable	-15,000	15,000
Accrued Payroll	161,475	'
Net cash used by operating activities	-172,832	-2,510
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'
Net cash used by investing activities	'	'
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'
Issuance of common stock	'	508,206
Net cash provided by financing activities	'	508,206
Net (decrease) increase in cash	-172,832	505,696
Cash, beginning of period	505,696	'
Cash, end of period	332,864	505,696
SUPPLEMENTAL CASH FLOW INFORMATION:	'	'
Issuance of common stock for services	$2,589	$15,000

Background_Information

Background Information	12 Months Ended
	Jun. 30, 2014
Notes to Financial Statements	'
Background Information	'
	1	Background Information
	NanoAntibiotics, Inc. (the “Company”) is a development stage enterprise that was incorporated in the state of Nevada on April 10, 2013.  To date, the Company’s activities have been limited to raising capital, organizational matters, and the structuring of its business plan. On January 1, 2014 we moved our corporate office from Surfside, Florida to Beverly, Massachusetts.
	We are an early stage biotechnology company engaged in the discovery, development and commercialization of new classes of broad spectrum antibiotics for gram-negative and gram-positive bacterial infections, including some of the most difficult-to-treat Multi Drug Resistant Bacteria, also called “Superbugs.” Our drug discovery platform currently provides a multi-pronged level understanding of interactions between drug candidates and their bacterial targets and enables us to engineer antibiotics with enhanced characteristics to attack a Drug Resistant Bacteria with a multi-targeted approach. Our pharmaceutical compounds originated at Kard Scientific, Inc. (“Kard”), a preclinical contract research organization founded by our President Rajah Menon in 2002 and of which Mr. Menon is its principal shareholder. These compounds were composed and formulated by researchers at Kard who then conducted in-vitro studies. On October 3, 2013, Kard and Mr. Menon assigned all of their rights, formulations, and all studies and data related to efflux pump antibiotics to the Company. The candidates have been studied in cell-based assays (in-vitro), but have not been studied in small animals (in-vivo) or animals with drug resistant bacteria for efficacy, efficiency and toxicity. We currently own all development and marketing rights to our products. We plan on contracting research and development of our technologies to third parties. The Company intends to file patent applications for each of these candidates as studies advance and funds become available.
	According to ASC 845-10-S99, transfers of non-monetary assets to a company by its promoters or shareholders in exchange for stock prior to or at the time of the entity’s initial public offering should be recorded at the transferors' historical cost basis determined under GAAP.  As such the cost basis carried on Kard’s books and records was zero.  Therefore, the accounting principles in ASC 845-10-S99 were followed and the Company recorded the rights at its historical cost basis, which was at the historical cost basis of zero. Although the transfer was at $1, this amount was determined by the Company to be deminimus and immaterial.

Going_Concern

Going Concern	12 Months Ended
	Jun. 30, 2014
Notes to Financial Statements	'
Going Concern	'
	2	Going Concern
	The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. For the year ended June 30, 2014, the Company had a net loss of $322,385.  As of June 30, 2014, the Company has not earned any revenues. In view of these matters, the Company’s ability to continue as a going concern is dependent upon the Company’s ability to begin operations and to achieve a level of profitability. Since inception, the Company has financed its activities principally from the sale of public equity securities. The Company intends on financing its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes and proceeds from sub-licensing agreements until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Significant_Accounting_Policie

Significant Accounting Policies	12 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Significant Accounting Policies	'
	3	Significant Accounting Policies
	Basis of Presentation
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
	Cash
	Cash is maintained at financial institutions and, at times, balances may exceed federally insured limits. We have never experienced any losses related to these balances. All of our non-interest bearing cash balances were fully insured at June 30, 2014, and our interest bearing cash balances may exceed federally insured limits.
	Financial Instruments
	The Company’s financial instruments include cash and accounts payable. The carrying amounts of cash and accounts payable approximate their fair value, due to the short-term nature of these items.
	Research and Development
	Research and development costs are charged to operations when incurred and are included in operating expenses. The Company expensed $49,419 for research and development for the year ended June 30, 2014.
	Income Taxes
	Deferred income tax assets and liabilities arise from temporary differences associated with differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted tax rates, which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities are classified as current or non-current, depending on the classification of the assets or liabilities to which they relate. Deferred tax assets and liabilities not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse.
	The Company follows the provisions of FASB ASC 740-10 “Uncertainty in Income Taxes” (ASC 740-10), January 1, 2007. The Company has not recognized a liability as a result of the implementation of ASC 740-10. A reconciliation of the beginning and ending amount of unrecognized tax benefits has not been provided since there are no unrecognized benefits at June 30, 2014 and since the date of adoption. The Company has not recognized interest expense or penalties as a result of the implementation of ASC 740-10. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses.
	Earnings (Loss) per Share
	Basic earnings per share are computed by dividing net income by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share are computed by dividing net income by the weighted average number of shares of common stock outstanding and dilutive options outstanding during the year. The Company did not have any common stock equivalents for the period ended June 30, 2014.
	Stock-based Compensation
	The Company recognizes all share-based payments to employees, including grants of employee stock options, as compensation expense in the financial statements based on their fair values. That expense will be recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).
	On February 20, 2014, the Company entered into a two year agreement with a Consultant to serve as a scientific advisor and to participate as a member of the Company’s Scientific Advisory Board.  In exchange for these services, the Company has granted the Consultant 100,000 shares of common stock.  On February 24, 2014, the Company entered into a two year agreement with a consultant to serve as a scientific adviser and to participate as a member of the Company’s Scientific Advisory Board. In exchange for these services, the Company has granted the Consultant 50,000 shares of common stock.  The 150,000 shares of common stock are valued at a total of $15,000 and recorded in prepaid expenses.  For the year ended June 30, $2,589 has been expensed.
	Fair Value Measurements
	In September 2006, the Financial Accounting Standards Board (FASB) introduced a framework for measuring fair value and expanded required disclosure about fair value measurements of assets and liabilities. The Company adopted the standard for those financial assets and liabilities as of the beginning of the 2013fiscal year and the impact of adoption was not significant. FASB Accounting Standards Codification (ASC) 820 “Fair Value Measurements and Disclosures” (ASC 820) defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:
	Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
	Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.
	Level 3 - Inputs that are both significant to the fair value measurement and unobservable.
	Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of June 30, 2014. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accrued payroll.
	Recent accounting pronouncements
	In June 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-10, “Development Stage Entities (Topic 915) Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation”. This ASU does the following among other things: a) eliminates the requirement to present inception-to-date information on the statements of income, cash flows, and shareholders’ equity, b) eliminates the need to label the financial statements as those of a development stage entity, c) eliminates the need to disclose a description of the development stage activities in which the entity is engaged, and d) amends FASB ASC 275, Risks and Uncertainties, to clarify that information on risks and uncertainties for entities that have not commenced planned principal operations is required. The amendments in ASU No. 2014-10 related to the elimination of Topic 915 disclosures and the additional disclosure for Topic 275 are effective for public companies for annual and interim reporting periods beginning after December 15, 2014. Early adoption is permitted. The Company has evaluated this ASU and determined that it will early adopt beginning with the period ended June 30, 2014.
	Other recent accounting pronouncements issued by the FASB (including its EITF), the AICPA, and the SEC did not or are not believed by management to have a material impact on the Company’s financial statements.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Jun. 30, 2014
Notes to Financial Statements	'
Commitments and Contingencies	'
	4. Commitments and Contingencies
	Office Lease
	On January 1, 2014 the company executed a lease agreement with Cummings Properties for the company’s office of 270 square feet at 100 Cummings Center, Suite 247-C, Beverly, MA 01915. The lease is for a term of five years from January 1, 2014 to December 30, 2018 and requires monthly payments of $357 ($4,284 annually for each of the five years, total aggregate of $21,420).
	Employment Agreement
	During the year ended June 30, 2014, the Company entered into an employment agreement with the Company’s Chief Executive Officer and Chief Financial Officer for $150,000 annual salary. The agreementis effective beginning July 1, 2013 and expires on June 30, 2015.

Income_Taxes

Income Taxes	12 Months Ended
	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	5	Income Taxes
	Deferred taxes are recorded for all existing temporary differences in the Company’s assets and liabilities for income tax and financial reporting purposes. Due to the valuation allowance for deferred tax assets, as noted below, there was no net deferred tax benefit or expense for the year ended June 30, 2014.
	There is no current or deferred income tax expense or benefit allocated to continuing operations for the year ended June 30, 2014.
	The provision for income taxes is different from that which would be obtained by applying the statutory federal income tax rate to income before income taxes. The items causing this difference are as follows:
			30-Jun-14			30-Jun-13
	Tax expense (benefit) at U.S. statutory rate		$	(109,400	)	$	(6,000	)
	State income tax expense (benefit), net of federal benefit			(16,100	)		(900	)
	Effect of non-deductible expenses			—			—
	Other			—			—
	Change in valuation allowance			125,500			6,900
			$	—		$	—
	The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at June 30, 2014 are as follows:
	Deferred tax assets (liability), noncurrent:
	Net operating loss		$	132,400
	Valuation allowance			(132,400	)
			$	—
	Change in valuation allowance:
	Balance, June 30, 2013		$	6,900
	Increase in valuation allowance			125,500
	Balance, June 30, 2014			132,400
	Since management of the Company believes that it is more likely than not that the net deferred tax assets will not provide future benefit, the Company has established a 100 percent valuation allowance on the net deferred tax assets as of June 30, 2014.
	As of June 30, 2014, the Company had federal and state net operating loss carry-forwards totaling approximately $339,400 which begin expiring in 2022.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Jun. 30, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	6	Related Party Transactions
	On May 20, 2014, the Company issued 19,000,000 common shares to a director and officer for cash consideration of $0.0001 per share.
	On May 28, 2014, the Company issued 15,000,000 common shares to a director and officer for cash consideration of $0.0001 per share.
	The above terms and amounts are not necessarily indicative of the terms and amounts that would have been incurred had comparable transactions been entered into with independent parties.

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash	'
	Cash
	Cash is maintained at financial institutions and, at times, balances may exceed federally insured limits. We have never experienced any losses related to these balances. All of our non-interest bearing cash balances were fully insured at June 30, 2014, and our interest bearing cash balances may exceed federally insured limits.
Financial Instruments	'
	Financial Instruments
	The Company’s financial instruments include cash and accounts payable. The carrying amounts of cash and accounts payable approximate their fair value, due to the short-term nature of these items.
Research and Development	'
	Research and Development
	Research and development costs are charged to operations when incurred and are included in operating expenses. The Company expensed $49,419 for research and development for the year ended June 30, 2014.
Income Taxes	'
	Income Taxes
	Deferred income tax assets and liabilities arise from temporary differences associated with differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted tax rates, which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities are classified as current or non-current, depending on the classification of the assets or liabilities to which they relate. Deferred tax assets and liabilities not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse.
	The Company follows the provisions of FASB ASC 740-10 “Uncertainty in Income Taxes” (ASC 740-10), January 1, 2007. The Company has not recognized a liability as a result of the implementation of ASC 740-10. A reconciliation of the beginning and ending amount of unrecognized tax benefits has not been provided since there are no unrecognized benefits at June 30, 2014 and since the date of adoption. The Company has not recognized interest expense or penalties as a result of the implementation of ASC 740-10. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses.
Earnings (Loss) per Share	'
	Earnings (Loss) per Share
	Basic earnings per share are computed by dividing net income by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share are computed by dividing net income by the weighted average number of shares of common stock outstanding and dilutive options outstanding during the year. The Company did not have any common stock equivalents for the period ended June 30, 2014.
Stock-based Compensation	'
	Stock-based Compensation
	The Company recognizes all share-based payments to employees, including grants of employee stock options, as compensation expense in the financial statements based on their fair values. That expense will be recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).
	On February 20, 2014, the Company entered into a two year agreement with a Consultant to serve as a scientific advisor and to participate as a member of the Company’s Scientific Advisory Board.  In exchange for these services, the Company has granted the Consultant 100,000 shares of common stock.  On February 24, 2014, the Company entered into a two year agreement with a consultant to serve as a scientific adviser and to participate as a member of the Company’s Scientific Advisory Board. In exchange for these services, the Company has granted the Consultant 50,000 shares of common stock.  The 150,000 shares of common stock are valued at a total of $15,000 and recorded in prepaid expenses.  For the year ended June 30, $2,589 has been expensed.
Fair Value Measurements	'
	Fair Value Measurements
	In September 2006, the Financial Accounting Standards Board (FASB) introduced a framework for measuring fair value and expanded required disclosure about fair value measurements of assets and liabilities. The Company adopted the standard for those financial assets and liabilities as of the beginning of the 2013 fiscal year and the impact of adoption was not significant. FASB Accounting Standards Codification (ASC) 820 “Fair Value Measurements and Disclosures” (ASC 820) defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:
	Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
	Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.
	Level 3 - Inputs that are both significant to the fair value measurement and unobservable.
	Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of June 30, 2014. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accrued payroll.
Recent accounting pronouncements	'
	Recent accounting pronouncements
	In June 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-10, “Development Stage Entities (Topic 915) Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation”. This ASU does the following among other things: a) eliminates the requirement to present inception-to-date information on the statements of income, cash flows, and shareholders’ equity, b) eliminates the need to label the financial statements as those of a development stage entity, c) eliminates the need to disclose a description of the development stage activities in which the entity is engaged, and d) amends FASB ASC 275, Risks and Uncertainties, to clarify that information on risks and uncertainties for entities that have not commenced planned principal operations is required. The amendments in ASU No. 2014-10 related to the elimination of Topic 915 disclosures and the additional disclosure for Topic 275 are effective for public companies for annual and interim reporting periods beginning after December 15, 2014. Early adoption is permitted. The Company has evaluated this ASU and determined that it will early adopt beginning with the period ended June 30, 2014.
	Other recent accounting pronouncements issued by the FASB (including its EITF), the AICPA, and the SEC did not or are not believed by management to have a material impact on the Company’s financial statements.

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
Reconciliation of the federal statutory income tax rate to income tax expense expense	'
		30-Jun-14			30-Jun-13
	Tax expense (benefit) at U.S. statutory rate	$	(109,400	)	$	(6,000	)
	State income tax expense (benefit), net of federal benefit		(16,100	)		(900	)
	Effect of non-deductible expenses		—			—
	Other		—			—
	Change in valuation allowance		125,500			6,900
		$	—		$	—
Schedule of gross amounts of deferred tax assets and deferred tax liabilities	'
	The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at June 30, 2014 are as follows:
	Deferred tax assets (liability), noncurrent:
	Net operating loss	$	132,400
	Valuation allowance		(132,400	)
		$	—
	Change in valuation allowance:
	Balance, June 30, 2013	$	6,900
	Increase in valuation allowance		125,500
	Balance, June 30, 2014		132,400

Going_Concern_Details_Narrativ

Going Concern (Details Narrative) (USD $)	3 Months Ended	12 Months Ended
	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Notes to Financial Statements	'	'	'
Net Loss	$17,510	$321,896	$17,510

Commitments_and_Contingencies_

Commitments and Contingencies (Details Narrative) (USD $)	1 Months Ended	12 Months Ended	60 Months Ended
	Jan. 31, 2014	Dec. 31, 2014	Dec. 30, 2018
Notes to Financial Statements	'	'	'
Lease rental	$357	$4,284	$21,420
Lease term (in years)	'5 years	'	'

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Income Tax Disclosure [Abstract]	'	'
Tax expense (benefit) at U.S. statutory rate	($109,400)	($6,000)
State income tax expense (benefit), net of federal benefit	-16,100	-900
Effect of non-deductible expenses	'	'
Other	'	'
Change in valuation allowance	125,500	6,900
Total	'	'

Income_Taxes_Details_2

Income Taxes (Details 2) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Income Taxes Details 2	'	'
Net operating loss	$132,400	'
Valuation allowance	132,400	6,900
Total	'	'

Income_Taxes_Details_3

Income Taxes (Details 3) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Change in valuation allowance:	'	'
Beginning Balance	$6,900	'
Increase in valuation allowance	125,500	6,900
Ending Balance	132,400	6,900
Federal and State net operating loss carry-forwards	$339,400	'

Related_Party_Transactions_Det

Related Party Transactions (Details Narrative) (USD $)	Jun. 30, 2014	28-May-14	20-May-14
		Director and Officer [Member]	Director and Officer [Member]
Shares issued for cash	'	15,000,000	19,000,000
Shares issued, price per share	$0.10	$0.00	$0.00